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ARTICLE OPEN
TP53 protein levels, RNA-based pathway assessment, and race
among invasive breast cancer cases
Lindsay A. Williams1, Ebonee N. Butler1, Xuezheng Sun1, Emma H. Allott2, Stephanie M. Cohen3, Ashley M. Fuller 4,
Katherine A. Hoadley3,5, Charles M. Perou5, Joseph Geradts6, Andrew F. Olshan1 and Melissa A. Troester1,3,4
Mutations in tumor suppressor TP53 have been inconsistently linked to breast cancer risk factors and survival.
Immunohistochemistry (IHC) staining, a primary clinical means of TP53 mutation determination, only detects mutations that
facilitate protein accumulation (e.g., missense mutations). RNA-based pathway methods capture functional status and may aid in
understanding the role of TP53 function in racial disparities of breast cancer. TP53 status was assessed among invasive breast
cancer cases from the Carolina Breast Cancer Study (CBCS) (2008–2013) using IHC and an established RNA-based TP53 signature
(CBCS and The Cancer Genome Atlas (TCGA)). Frequency of TP53 status (IHC, RNA-based) was estimated in association with tumor
characteristics, PAM50 intrinsic subtype, age, and race using relative frequency differences (RFDs) and 95% conﬁdence intervals
(95% CI) as the measure of association. Approximately 60% of basal-like tumors were TP53 protein positive (IHC), while nearly 100%
were TP53 mutant-like (RNA). Luminal A tumors had low frequency of TP53 positivity (IHC: 7.9%) and mutant-like status (RNA: 1.7%).
Mutant-like TP53 (RNA) was strongly associated with age ≤50 years, high tumor grade, advanced stage of disease, large tumor size,
and basal-like and HER2 intrinsic subtypes. Black race was strongly associated with TP53 mutant-like status (RNA) (RFD: 24.8%, 95%
CI: 20.5, 29.0) even after adjusting for age, grade, stage (RFD: 11.3%; 95% CI: 7.6, 15.0). Associations were attenuated and non-
signiﬁcant when measured by IHC. IHC-based TP53 status is an insensitive measurement of TP53 functional status. RNA-based
methods suggest a role for TP53 in tumor prognostic features and racial disparities.
npj Breast Cancer  (2018) 4:13 ; doi:10.1038/s41523-018-0067-5
INTRODUCTION
The tumor suppressor gene TP53 is mutated in 30–40% of breast
tumors, with variation in mutation frequency by intrinsic subtype
and race.1–14 Up to 80% of basal-like and 70% of human epidermal
growth factor 2-enriched (HER2-enriched) breast tumors harbor
TP53 mutations, which commonly include nonsense and frame
shift alterations.1 Mutations occur at much lower frequencies
among Luminal A (12–23%) and Luminal B (15–29%)
tumors1,2,9,13–15 and are primarily missense mutations in form. In
addition, TP53 mutation rates are higher among black women
(25–32%) compared to white women (7–23%),11,16 which may
potentially help to explain existing racial disparities in breast
cancer incidence and survival. Many previous studies that have
evaluated race and TP53 status have used immunohistochemistry
(IHC) methods that detect missense mutations resulting in protein
accumulation. Moreover, recent analyses based on The Cancer
Genome Atlas (TCGA) data also detected racial differences in the
frequency of TP53 mutations based on DNA sequence.1,17
Recently, several studies have used RNA-based methods to
determine TP53 functional status. This approach avoids some
functional misclassiﬁcation that could result from the low
sensitivity of IHC and the low speciﬁcity of TP53 sequence
mutations for detecting functional defects in the TP53
pathway.18–20 Using this approach, we applied a validated, 52-
gene signature18 to evaluate the RNA expression of TP53-
dependent genes, classifying 1013 invasive breast tumors from
Phase 3 of the population-based CBCS as TP53 mutant-like or wild-
type-like. RNA-based TP53 status was compared to IHC status (n=
1291 total, n= 843 RNA and IHC), and both were evaluated in
association with race, age, tumor characteristics, and PAM50
intrinsic subtype. Results were placed in context of parallel
analyses of TCGA data using the same TP53-dependent gene
expression signature and whole genome DNA sequencing data.
RESULTS
The frequency of TP53 protein overexpression (IHC) and TP53
mutant-like status (RNA) within categories of age, race, and
selected tumor characteristics is presented in Table 1. Signiﬁcant
differences in TP53 protein overexpression were observed for
grade, stage, tumor size, and PAM50 subtype. ER−, PR−, HER2+,
and Triple Negative (ER−/PR−/HER2−) tumors more frequently
overexpressed TP53. There were no differences in TP53 protein
overexpression by age or lymph node status.
The patterns of association observed for TP53 protein over-
expression were qualitatively similar, but stronger in magnitude
when using RNA-based methods (Table 1). TP53 mutant-like status
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was associated with age ≤50 years, high tumor grade, higher stage
of disease, node positive disease, larger tumors (>2 cm), ER−, PR−,
HER2+, Triple Negative (ER-/PR-/HER2-) tumors, and non-Luminal
PAM50 subtypes (basal-like, HER2-enriched, Normal-like). Compar-
ing RNA-based calls to IHC-based calls, 77.7% of IHC mutant/TP53
over-expressing tumors were mutant-like by RNA; however, many
tumors that appear to be TP53 wild type by IHC have RNA-based
proﬁles suggestive of TP53 loss (223 of 623; 30%) (Supplemental
Table 2).
Table 2 presents TP53 status (IHC and RNA-based), overall and
stratiﬁed by PAM50 subtype (CBCS3 and TCGA). In CBCS3, more
tumors had TP53 mutant-like status (41.0%) than TP53 over-
expression (21.3%). The increased frequency of mutant-like status
by RNA-based methods was observed among basal-like (RNA:
99.4% vs. IHC: 58.1%), Luminal B (RNA: 44.3% vs. IHC: 16.3%), and
HER2-enriched (RNA: 95.8% vs. IHC: 29.4%) subtypes. Lower
frequencies of TP53 mutant-like status using RNA were observed
among Luminal A (RNA: 1.7% vs. IHC: 7.9%), and normal-like
Table 1. Associations between patient and tumor characteristics and TP53 status (IHC, RNA) in CBCS3
IHC average weighted percent Positivity ≥10% NanoString TP53 gene expression signature
Mutant (≥10%) Wild type (<10%) Mutant Wild type
N (%a) N (%a) RFDb (95% CI) p-value N (%a) N (%a) RFDb (95% CI) p-value
Total 312 (21.3) 979 (78.7) 491 (40.9) 522 (59.1)
Age
≤50 years 145 (29.8) 461 (28.0) 1.8 (−1.7, 5.3) 0.31 263 (34.4) 247 (28.6) 5.8 (2.4, 9.2) <0.01
>50 years 167 (70.2) 518 (72.0) Ref. 228 (65.6) 275 (71.4) Ref.
Grade
Low-Intermediate 65 (28.6) 620 (75.0) Ref. 102 (26.2) 392 (82.2) Ref.
High 232 (71.4) 295 (25.0) 46.4 (42.8, 49.9) <0.01 381 (73.8) 108 (17.8) 56.0 (52.9, 59.1) <0.01
Missing 15 64 8 22
Stage
I, II 259 (84.3) 848 (88.9) Ref. 392 (80.3) 449 (87.2) Ref.
III, IV 51 (15.7) 118 (11.1) 4.5 (1.8, 7.2) <0.01 98 (19.7) 68 (12.8) 6.9 (4.2, 9.6) <0.01
Missing 2 13 1 5
Node Status
positive 108 (33.8) 363 (32.7) 1.1 (-2.5, 4.7) 0.54 222 (44.3) 204 (36.6) 7.7 (4.1, 11.2) <0.01
negative 202 (66.2) 614 (67.3) Ref. 267 (55.7) 317 (63.4) Ref.
missing 2 2 2 1
Tumor Size
≤2 cm 159 (57.1) 570 (64.9) Ref. 199 (44.4) 306 (64.3) Ref.
>2 cm 149 (42.9) 382 (35.1) 7.8 (0.4, 11.5) <0.01 288 (55.6) 208 (35.7) 19.9 (16.3, 23.5) <0.01
missing 4 27 4 8
ER Status
positive 118 (46.6) 800 (86.7) Ref. <0.01 207 (44.6) 487 (96.5) Ref.
negative 190 (53.4) 153 (13.3) 40.1 (36.5, 43.7) 280 (55.4) 27 (3.5) 51.9 (49.0, 54.8) <0.01
missing 4 26 4 8
PR Status
positive 83 (33.9) 634 (69.1) Ref. <0.01 140 (29.8) 408 (82.5) Ref.
negative 223 (66.1) 316 (30.9) 35.2 (31.6, 38.9) 343 (70.2) 103 (17.5) 52.7 (49.5, 55.8) <0.01
missing 6 29 8 11
HER2 Status
negative 251 (83.9) 821 (88.4) Ref. 379 (79.8) 469 (94.0) Ref.
positive 54 (16.1) 117 (11.6) 4.5 (1.8, 7.3) <0.01 101 (20.2) 38 (6.0) 14.2 (11.7, 16.7) <0.01
missing 7 41 11 15
HR+/Her2−
ER+ or PR+/HER2− 90 (45.7) 707 (89.1) Ref. 152 (43.2) 448 (97.1) Ref.
ER-/PR-/HER2− 158 (54.3) 112 (10.9) 43.3 (39.4, 47.2) <0.01 224 (56.8) 21 (2.9) 53.8 (50.6, 57.1) <0.01
missing 64 160 115 53
PAM50 Subtype
Luminal A/B 59 (30.1) 441 (74.5) Ref. 111 (22.5) 476 (91.8) Ref.
Basal-like, HER2, Normal-like 161 (69.9) 182 (25.5) 44.4 (40.2, 48.7) <0.01 380 (77.5) 46 (8.2) 69.3 (66.6, 71.9) <0.01
missing 92 356
aPercentages weighted for sampling design, models adjusted for sampling design
bRFD: Relative frequency difference
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tumors (RNA: 19.9% vs. IHC: 21.5%). Compared to DNA-based
methods, RNA-based methods appeared to detect a higher
proportion of TP53 mutant-like tumors in TCGA (52.6% mutant-
like compared to 35.2% mutant by DNA sequencing). In subtype-
stratiﬁed analyses, RNA-based assessments detected more
mutant-like tumors relative to DNA sequencing among basal-like
(RNA: 98.2% vs. DNA: 89.6%), Luminal A (RNA: 25.4% vs. DNA:
11.7%), Luminal B (RNA: 78.4% vs. DNA: 33.1%), and HER2-
enriched (RNA: 86.8% vs. DNA: 68.0%) tumors, but not among
normal-like tumors (RNA: 40.5% vs. DNA: 45.2%).
Black race was strongly associated with TP53 status in CBCS3 and
TCGA (Table 3), particularly for the RNA-based signature. Among
Luminal A/B tumors, by both clinical subtype or PAM50 subtype,
black women were signiﬁcantly more likely to have TP53 mutant-like
status when measured by RNA (black vs. white RFD: 17.4%; 95% CI:
12.3, 22.6 for clinical subtype; black vs. white RFD: 13.5%; 95% CI: 8.5,
18.5 for PAM50 subtype) (Fig. 1). These differences were not evident
when considering TP53 status measured by IHC. In univariate
analyses of CBCS3 data, black women had a signiﬁcantly higher
proportion of TP53 overexpression and TP53 mutant-like status than
white women (IHC: RFD: 11.0%, 95% CI: 7.6, 14.5; RNA: RFD: 24.8%,
95% CI: 20.5, 29.0). TCGA RNA-based results also showed higher
frequency of TP53 mutant-like status in black women (RFD: 19.9%,
95% CI: 12.0, 27.9). Upon adjustment for age and stage in TCGA, and
age, stage, and grade in CBCS3, TP53 mutant-like status remained
signiﬁcantly associated with black race. However, the association
between TP53 mutant status and black race in both TCGA and
CBCS3 was not statistically signiﬁcant by IHC (CBCS3) or RNA (CBCS3,
TCGA) when accounting for PAM50 intrinsic subtype along with the
other covariates.
To explore whether TP53-race associations were robust to
differences in age, we further evaluated associations between
tumor subtype and TP53 status after cross-classifying on both age
and race and three-marker clinical subtypes (Supplemental Table
3). Among IHC-based Triple Negative (ER−, PR−, HER2−) tumors,
black women ≤50 years of age had a higher frequency of TP53
protein overexpression (63.7%) and TP53 mutant-like status
(95.0%) than white women ≤50 years of age (IHC: 46.5%; RNA:
87.2%) and black and white women >50 years of age (black
women >50 IHC: 60.0%; RNA: 88.8%; white women >50 IHC: 56.8%;
RNA: 94.8%). After restricting these analyses to the more clinically
homogenous group of ER+ or PR+, or hormone receptor-positive
(HR+), and HER2- tumors, race and age remained statistically
signiﬁcantly associated with RNA-based TP53 mutant-like status
with black women ≤50 years of age having the highest frequency
of mutant-like status (39.9%), but this difference did not persist for
TP53 protein overexpression. HER2-positive tumors were unable
Table 2. Frequency of TP53 mutation by PAM50 subtype and technical method in CBCS3 and TCGA
Overall Basal-like Luminal A Luminal B HER2-enriched Normal-like
Study Method N (%a) TP53
mutant
N (%a) TP53
mutant
N (%a) TP53
mutant
N (%a) TP53
mutant
N (%a) TP53
mutant
N (%a) TP53
mutant
CBCS3 IHC 312 (21.3) 120 (58.1) 29 (7.9) 30 (16.3) 34 (29.4) 7 (21.5)
RNA-based 491 (41.0) 256 (99.4) 11 (1.7) 100 (44.3) 114 (95.8) 10 (19.9)
TCGA RNA-based 475 (52.6) 167 (98.2) 123 (25.4) 124 (78.4) 46 (86.8) 15 (40.5)
DNA-based missense
mutations
164 (20.2) 65 (42.2) 32 (7.5) 33 (22.3) 22 (44.0) 12 (38.7)
any mutation 285 (35.2) 138 (89.6) 50 (11.7) 49 (33.1) 34 (68.0) 14 (45.2)
wild-type 526 (64.9) 16 (10.4) 378 (88.3) 99 (66.9) 16 (32.0) 17 (54.8)
aPercentages weighted for sampling design
Table 3. Association between race and TP53 expression and mutation status by technical method, CBCS3 and TCGA
White Black Univariateb Multivariate I Multivariate II
Method (N,%) (N,%) RFD (95% CI) p-value RFD (95% CI) p-value RFD (95% CI) p-value
CBCS3a
IHC
wild type 490 (81.2)a 425 (70.2)a Ref. Ref. Ref.
mutant 117 (18.8)a 180 (29.8)a 11.0 (7.6, 14.5) <0.01 2.8 (−0.2, 5.8)c 0.07 −0.3 (−3.4, 2.9)e 0.86
RNA-based
wild type 316 (64.1)a 184 (39.4)a Ref. Ref. Ref.
mutant 183 (35.7)a 300 (60.6)a 24.8 (20.5, 29.0) <0.01 11.3 (7.6, 15.0)c <0.01 3.2 (−1.6, 7.9)e 0.19
TCGA
RNA-based
wild type 372 (51.2) 51 (31.3) Ref. Ref. Ref.
mutant 354 (48.8) 112 (68.7) 19.9 (12.0, 27.9) <0.01 19.3 (11.4, 27.3)d <0.01 2.3 (−6.6, 11.2)f 0.61
aPercentages weighted for sampling design, CBCS3 models adjusted for sampling weights
bUnivariate analyses restricted to same set of participants in multivariate model I
cAdjusted for age, stage and grade
dAdjusted for age and stage
eAdjusted for age, stage, grade, and PAM50 subtype
fAdjusted for age, stage, and PAM50 subtype
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to be evaluated in these additional analyses due to low sample
size.
DISCUSSION
In our study, nearly twice as many breast tumors were classiﬁed as
TP53 mutant-like when using RNA-based gene expression
compared to IHC, consistent with the observation that IHC
methods miss many mutations that are not associated with
TP53 protein overexpression. This improved sensitivity to detect
functional defects in the TP53 pathway resulted in stronger
associations with almost all clinical and demographic variables,
including age, grade, stage, node status, tumor size and molecular
subtype. When using TCGA data to compare RNA-based
classiﬁcation of TP53 status to DNA-based mutation detection,
the gene expression signature is also more sensitive, in line with
the observation that some defects in the TP53 pathway arise from
other genetic events not captured by TP53 protein expression
alone (e.g., MDM2 ampliﬁcation). All of the changes in TP53 gene
dosimetry (ampliﬁcation and deletion) and all relevant regulators
of TP53 expression and function, such as MDM2, p63, p21 (both up
and downstream), are incompletely understood, so we cannot
conﬁrm that all tumors showing RNA-based mutant-like status
have underlying genetic or epigenetic defects in the pathway.
However, the TP53 signature used for this analysis has been
validated in TCGA analyses,1 and is based on human cell line
studies with isogenic knockdown of TP53.18 Moreover, patterns of
association between molecular subtype and TP53 status observed
in the CBCS were similar to patterns observed in TCGA, with
almost all basal-like tumors and very few Luminal A tumors
showing mutant-like TP53 signatures or DNA-based mutations.
One metric for assessing the utility of the RNA-based signature
is to assess whether the signature recapitulates some of the
patterns of TP53 mutation by clinical variables. Indeed, our results
are consistent with several previous studies. We and others have
found that higher grade tumors are more frequently classiﬁed as
TP53 mutant by DNA sequencing and protein expression.14,21–23
Additionally, we observed RNA-based mutant-like TP53 status was
more common among cases diagnosed with node positive or
higher stage of disease, as reported by others using DNA or IHC-
based methods.14,23–25 Tumors greater than 2 cm in size also more
frequently overexpressed TP53 and were more frequently TP53
mutant-like, similar to what has been reported previously.14,23
However, our results also show that the relative sensitivity of the
TP53 signature may afford some advantages. For example, RNA-
based TP53 mutant-like status was associated with younger age
(≤50 years), but TP53 overexpression was not. In previous studies,
age has been inconsistently linked to TP53 status.14,21 It is possible
that other inconsistencies in previous studies may in part lie in
misclassiﬁcation of TP53 functional status.
Given the established mortality disparities by race and the
prognostic value of TP53 mutation status,15,26 our primary hypoth-
esis was that TP53 functional defects would be more common with
black race. We found that black women had higher frequencies of
TP53 mutations and TP53 mutant-like status than white women,
consistent with previous studies.1,11,12,16,17,25,27 Further, we observed
a signiﬁcant difference in the relative frequencies of TP53 mutant-
like status for black compared to white women when restricted to
Luminal A/B clinical and PAM50 subtypes. Differences were
imprecise and not signiﬁcant when comparing black and white
women for Triple Negative or basal-like tumors as these subtypes
had over 90% of black and white women classiﬁed as TP53 mutant
by both IHC and RNA (results not shown). Given a large sample size
of black women (n > 500 in CBCS3 compared to ~150 in TCGA), we
were able to evaluate age and race simultaneously in CBCS3,
showing that young, black women have the highest rates of TP53
mutant-like status when compared to young white women and
older white and black women.
Our study should be viewed in light of some limitations. First, the
IHC measurements were taken from multiple TMA cores and not
whole slide images. While participants could have up to four cores
sampled from a single tissue block, there could be some differences
in the percent positivity for the whole tissue versus the averaged
percent positivity that we calculated weighted by core cellularity. All
sample top and bottom tissue block slides were analyzed by study
pathologists to ensure that the sample was of invasive disease, but
we cannot exclude the possibility of normal epithelium or DCIS
being counted by the automated algorithm for TP53 positivity. While
possible, we anticipate little impact on the ﬁnal results from this
phenomenon. Regarding IHC, we employed a positive stain
approach where binding of the TP53 antibody would signal a
mutation in TP53 resulting in accumulation of the protein within the
nucleus. There are other staining methods that could help to identify
the mutations that truncate theTP53 protein, but those were not
applied here. Similarly, to determine RNA gene expression for the
tissue samples two cores were taken and pooled for the PAM50
analysis. The use of multiple cores from different locations in the
tumor may or may not be representative of the gene expression of
the tumor as a whole. We believe that using multiple cores made our
gene expression proﬁles of the tumor more comprehensive, but this
precludes us from studying heterogeneity in gene expression within
the tumor. Finally, we did not have sufﬁcient sample size with RNA
data, nor sufﬁcient recurrence events to justify analyses of TP53-
dependent survivorship. Future work is planned to complete RNA-
based assessment of TP53 for the remainder of the CBCS3 cohort. In
addition, we are continuing to follow patients for recurrence and
survival so that the role of TP53 in outcome disparities, overall and
according to intrinsic subtype, can be assessed.
The methods and ﬁndings presented here show that the RNA-
based method we applied to detect functional defects in TP53 is
more sensitive than IHC and yields similar associations with
subtype and race as previously observed in other datasets, but
with greater sensitivity and stronger associations relative to IHC
methods. Future work should evaluate etiologic and survival
associations for TP53 based on RNA-based signatures particularly
by race where black women with ER+, HER2- disease have worse
outcomes than white women.28,29 An advantage of the current
method is that measuring RNA through methods like NanoString
assays can simultaneously measure tumor subtype (e.g., PAM50)
and TP53 mutant-like status in both fresh frozen and FFPE
Fig. 1 Relative frequency differences (RFDs) and 95% conﬁdence
interval (95% CI) for TP53 mutation status as determined by IHC and
RNA among black women compared to white women in Luminal A/
B clinical and PAM50 subtype cases only
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samples. Given recent ﬁndings that the prognostic value of TP53
may depend upon subtype,14 future analyses integrating subtype
and TP53 status will help ascertain the role of this pathway in
breast cancer outcomes and race-ethnicity mortality disparities.
METHODS
Study population
The present analysis includes invasive breast cancer cases from the
population-based CBCS, Phase 3 (CBCS3) (2008-2013). Methods for the
CBCS have been described in detail elsewhere.2,28,30–33 Brieﬂy, eligible
cases were women aged 20–74 years with a ﬁrst diagnosis of invasive
breast cancer, identiﬁed via rapid case ascertainment through the NC
Central Cancer Registry. The current analysis is restricted to cases who had
tumor tissue available for IHC analysis (N= 448), RNA isolation from
formalin ﬁxed parafﬁn embedded (FFPE) tissue (N= 170), or both (N=
843). A total of 1461 of the 2998 cases in CBCS3 were included. All study
procedures were approved by the University of North Carolina (UNC)
School of Medicine Institutional Review Board and participants provided
written informed consent.
TCGA population has been described previously.1,7 A total of 903
participants included in this analysis were enrolled from various medical
centers, provided informed consent for access to tumor tissue, and had
RNA expression data available. All TCGA samples were processed under the
approval of the respective Institutional Review Boards and participants
provided written informed consent.
TP53 status by IHC
Immunohistochemistry staining conditions were optimized using breast
tissue sections and human cell lines with established TP53 mutation status
[(wild type: MCF-7, SUM102), (p.R175H mismatch mutant: SKBR3)]. All cell
lines were purchased from the American Type Culture Collection and low-
passage cultures were prepared, with mycoplasma testing performed
regularly and conﬁrmed negative. IHC was carried out at the UNC
Translational Pathology Laboratory using a Bond Autostainer (Leica
Microsystems Inc. Norwell, MA 02061). Slides were dewaxed in Bond
Dewax solution (AR9222) and hydrated in Bond Wash solution (AR9590).
Antigen retrieval was performed for 20min in Bond-Epitope Retrieval
Solution 1 pH-6.0 (AR9961). Slides were incubated for 15min with mouse
monoclonal anti-TP53 antibody (BioGenex, Fremont, CA; clone D07
[catalog # MU239-UC], 1:7200). Detection was performed using the Bond
Intense R Detection System (DS9263) supplemented with Dako EnVision
Mouse (Carpinteria, CA, K4001). Stained slides were counterstained with
hematoxylin, dehydrated, and coverslipped. A control tissue microarray
(TMA) containing TP53 positive and negative breast tissue and cell lines
was included in each run along with a negative control (no primary
antibody). CBCS3 TMA construction has been previously described.34 TMAs
were constructed with 1–4, 1.0-mm cores per participant.
TP53-stained TMA slides were scanned using the Aperio ScanScope XT
at 20× magniﬁcation. Details of the scoring algorithm have been described
previously.35 Brieﬂy, TP53 staining was measured with the Aperio
Nuclearv9 algorithm by quantifying the tumor cellularity and was
combined with the Genie Histology Pattern Recognition tool to correctly
classify the number of tumor and normal epithelial cells per core allowing
for enrichment of tumor cells. Algorithm parameters including nuclear size
and nuclear compactness were optimized to achieve the best nuclear
segmentation. The algorithm returned a total number of nuclei per core
and the number of nuclei positive for TP53. To determine the average
percent positivity, a method of core-to-case collapsing developed by Allott
et al.34 was used by summing the total number of nuclei/core (1–4 cores/
participant). Each core was given a weight equal to the number of core
nuclei divided by the total nuclei for the participant. For the core weighted
percent positivity, the core’s TP53 percent positivity was multiplied by the
core’s weight. The weighted core values were summed to obtain the
participant’s overall weighted percent TP53 positivity. Weighted percent
TP53 positivity was dichotomized to classify patients as negative or
positive (<10% for negative/wild-type, ≥10% positive/mutant). The ≥10%
cut point was selected based on the best sensitivity, speciﬁcity, and
accuracy measures.
Clinical characteristics of tumors
Data for estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) status, nodal status, and stage
of disease were abstracted from medical records for CBCS3 participants.
For CBCS3, tumor grade was deﬁned by central pathologist review by the
CBCS study pathologist.
PAM50 intrinsic subtype and TP53 status [RNA (CBCS3, TCGA) and
DNA-based (TCGA)]
In CBCS3, NanoString assays were conducted on 1122 samples from 1042
cases as described previously.34,36 Brieﬂy, hematoxylin and eosin stained
slides were reviewed by a pathologist and 1–9 1.0-mm cores were sampled
from tumor regions of corresponding blocks. Cases selected for NanoString
were randomized to three batches and technicians were blinded to tumor
characteristics and clinical data. Intrabatch QC data were reported
previously36 and showed high correlation among batch controls. RNA
was isolated using the Qiagen RNeasy FFPE kit (cat# 73504). NanoString
gene expression experiments, which use RNA counting as a measure of
gene expression, were conducted in the UNC Translational Genomics
Laboratory.
We excluded 39 samples with insufﬁcient quality as identiﬁed by the
NanoStringNorm package in Bioconductor and 18 samples from partici-
pants with two different tumor blocks. There were 52 patients with
multiple samples from the same tumor block. Gene expression data for
these participants was calculated as the RNA average of the samples if the
correlation coefﬁcients for expression were >0.90; otherwise the sample
with better quality score from NanoStringNorm was used. A total of 1013
cases were included in the ﬁnal analysis.
Two signatures were evaluated to classify patients: (1) the previously
validated 52-gene TP53-dependent signature18 and (2) a 50-gene
PAM50 signature.36 For the TP53 signature, mutant-like vs. normal-like class
was determined based on a similarity-to-centroid approach.18 For
PAM50 subtype, samples were categorized into one of ﬁve intrinsic subtypes
(Luminal A, Luminal B, basal-like, HER2-enriched, and Normal-like) as
described in Parker et al. 36,37
For TCGA, TP53 DNA mutations were determined (missense mutation,
any mutation) using the mutation annotation ﬁle (MAF) from the TCGA
breast lobular manuscript page (https://tcga-data.nci.nih.gov/docs/
publications/brca_2015/). RNA sequencing expression data from ﬂash
frozen invasive tumor tissue samples was used to classify patients
according to the PAM50 and TP53 signatures.7,37
Statistical analysis
Participant and tumor characteristics for the CBCS3 study population
overall, as well as the subsets with IHC (n= 1, 291) and NanoString data (n
= 1013) can be found in Supplemental Table 1. The IHC subset included all
samples with TMAs available, while the NanoString subset represented a
random sampling of CBC3 participants with at least two tumor tissue cores
remaining after TMA construction. The IHC subset differed signiﬁcantly
from CBCS3 as a whole by age at diagnosis, stage of disease, and tumor
size. The NanoString dataset differed from CBCS3 overall by grade. The IHC
and NanoString subset differed signiﬁcantly from one another by lymph
node status, tumor size, and tumor grade.
While the RNA-based data from CBCS3 was compared to similar data
from TCGA, patients in TCGA were more frequently older, more frequently
white, had larger tumors, and had high grade tumors (results not shown).
Generalized linear models were used to estimate relative frequency
differences (RFDs) and corresponding 95% Conﬁdence Intervals (95% CI) as
the measure of association between TP53 status and variables of interest.38
Sample size counts are unweighted and percentages are weighted to
account for the sampling design of CBCS3, which oversampled black and
younger women. Models are also adjusted for the sampling weights to
account for the study design. The following variables were studied in
association with TP53 status: age at diagnosis ( ≤ 50, > 50), race (self-report
black, non-black ( > 98% white, referred to as white)), tumor grade (low-
intermediate, high), stage of disease (I/II, III/IV), lymph node status (positive,
negative), tumor size ( ≤ 2 cm, > 2 cm), PAM50 intrinsic breast cancer subtype
(Luminal A, Luminal B, HER2-enriched, basal-like, Normal-like),37 ER status
(negative, positive), PR status (negative, positive), and HER2 status (negative,
positive). For subtype analyses, Luminal A/B was selected as the reference
group. RFDs by race are presented as univariate and multivariate-adjusted
(CBCS3: age, stage, grade, and PAM50 subtype; TCGA: age, stage, and
PAM50 subtype). All analyses were done in SAS version 9.4 (SAS Institute,
TP53 protein levels, RNA-based pathway assessment,
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Cary, NC). P-values were two-sided with an alpha value for statistical
signiﬁcance equal to 0.05.
Data availability
TCGA data can be found here: https://tcga-data.nci.nih.gov/docs/
publications/brca_2015/. The CBCS3 datasets generated and/or analyzed
during the current study are not publicly available due to some human
subjects restrictions, but may be available from the corresponding author
on reasonable request.
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